XENEXenon Pharmaceuticals Inc.
$35.35-16% 1Y
$35.35
$33.5052 weeks$70.97
Is the business good?
Good
1 good, 3 without dataMargins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margin direction, 3 years+17590.8 ptsderived
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is XENE?
- Share count, year on year
- +26%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2020 | −97% |
| FY2021 | −428% |
| FY2022 | −1369% |
| FY2025 | −4974% |
Details›
- Revenue, trailing twelve months
- $0
- Free cash flow, trailing twelve months
- −$339M
- Net income, trailing twelve months
- −$409M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.